298 related articles for article (PubMed ID: 17076986)
21. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
22. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
[TBL] [Abstract][Full Text] [Related]
23. The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer's disease.
Hatoum HT; Lin SJ; Arcona S; Thomas SK; Koumaras B; Mirski D
J Am Med Dir Assoc; 2005; 6(4):238-45. PubMed ID: 16005409
[TBL] [Abstract][Full Text] [Related]
24. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
Borkowska A; Ziolkowska-Kochan M; Rybakowski JK
Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
[TBL] [Abstract][Full Text] [Related]
25. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
[TBL] [Abstract][Full Text] [Related]
26. Discontinuation of rivastigmine in routine clinical practice.
Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1167-71. PubMed ID: 16315150
[TBL] [Abstract][Full Text] [Related]
27. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.
Gauthier S; Juby A; Rehel B; Schecter R
Int J Clin Pract; 2007 Jun; 61(6):886-95. PubMed ID: 17504350
[TBL] [Abstract][Full Text] [Related]
28. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
[TBL] [Abstract][Full Text] [Related]
29. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
30. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey.
Froelich L; Andreasen N; Tsolaki M; Foucher A; Kavanagh S; Baelen BV; Schwalen S
Curr Med Res Opin; 2009 Dec; 25(12):3059-68. PubMed ID: 19852697
[TBL] [Abstract][Full Text] [Related]
32. Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population.
Sinforiani E; Banchieri LM; Zucchella C; Bernasconi L; Nappi G
Funct Neurol; 2003; 18(4):233-7. PubMed ID: 15055749
[TBL] [Abstract][Full Text] [Related]
33. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
34. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
[TBL] [Abstract][Full Text] [Related]
35. [Impact of music therapy on anxiety and depression for patients with Alzheimer's disease and on the burden felt by the main caregiver (feasibility study)].
Guetin S; Portet F; Picot MC; Defez C; Pose C; Blayac JP; Touchon J
Encephale; 2009 Feb; 35(1):57-65. PubMed ID: 19250995
[TBL] [Abstract][Full Text] [Related]
36. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
37. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
[TBL] [Abstract][Full Text] [Related]
38. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
[TBL] [Abstract][Full Text] [Related]
39. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Farlow MR
Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
[TBL] [Abstract][Full Text] [Related]
40. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]